A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Renal Cell Carcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT03161145

CA209-770

Details and patient eligibility

About

A medical review chart study in Japan to describe the treatment patterns and outcomes of patients with kidney cancer that is unable to be removed by surgery or that has spread. The clinical data is to be abstracted using electronic data capture (eDC) from patient medical records in Japan.

Enrollment: 297 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Adults 20 years and older at the time of initial diagnosis of mRCC
• Alive or deceased as of the date of data collection
• Diagnosis of mRCC between 01-Jan-2012 and 31-Aug-2015

Exclusion Criteria:

• Previously and/or currently enrolled in RCC clinical trials
• Patients have primary cancer other than renal cell cancer

Trial design

297 participants in 1 patient group

Unresectable or metastatic renal cell carcinoma (mRCC)

Description:

Medical records will be reviewed for treatment patterns and outcomes